DENVER, April 22, 2022 – A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm ...
A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies. Findings from the ...
10don MSN
Early use of meds may lead to life-threatening conditions in preterm infants with heart defect
Babies born prematurely can have a number of complications at birth, simply because they are brought into the world before ...
In extremely preterm infants with a protocol-defined patent ductus arteriosus, death or bronchopulmonary dysplasia did not differ between the expectant management group and the active treatment group.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback